title: Influence of immunoglobulin isotype on therapeutic antibody function.
abstract: Monoclonal antibody (mAb) therapeutics are revolutionizing cancer treatment; however, not all tumors respond, and agent optimization is essential to improve outcome. It has become clear over recent years that isotype choice is vital to therapeutic success with agents that work through different mechanisms, direct tumor targeting, agonistic receptor engagement, or receptor-ligand blockade, having contrasting requirements. Here we summarize how isotype dictates mAb activity and discuss ways in which this information can be used for the development of enhanced therapeutics.
authors.affiliation: Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, United Kingdom.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Beers
authors.affiliation: Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, United Kingdom.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Glennie
authors.affiliation: Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, Faculty of Medicine, General Hospital, Southampton, United Kingdom.
authors.forename: Ann L
authors.initials: AL
authors.lastname: White
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000276:immunology*; D007155:Immunologic Factors / Q000276:immunology; D008954:Models, Biological; D017452:Receptors, IgG / Q000378:metabolism; D014612:Vaccines / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D007132:Immunoglobulin Isotypes; D007155:Immunologic Factors; D017452:Receptors, IgG; D014612:Vaccines